{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:53:23Z","timestamp":1791244403041,"version":"4.1.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T00:00:00Z","timestamp":1791158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"DOI":"10.1007\/s10067-026-08455-7","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T07:01:59Z","timestamp":1791183719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes after anifrolumab initiation in systemic lupus erythematosus: a pragmatic treat-to-target analysis"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0966-2778","authenticated-orcid":false,"given":"Dalifer Freites","family":"N\u00fa\u00f1ez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma Camarero","family":"Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara Rodr\u00edguez","family":"Montes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Mart\u00ednez","family":"Prada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina Lajas","family":"Petisco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Abasolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin Fern\u00e1ndez","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,5]]},"reference":[{"key":"8455_CR1","doi-asserted-by":"publisher","first-page":"ITC81","DOI":"10.7326\/AITC202006020","volume":"172","author":"M Kiriakidou","year":"2020","unstructured":"Kiriakidou M, Ching CL (2020) Systemic lupus erythematosus. Ann Intern Med 172:ITC81\u2013ITC96. https:\/\/doi.org\/10.7326\/AITC202006020","journal-title":"Ann Intern Med"},{"key":"8455_CR2","doi-asserted-by":"publisher","unstructured":"Elia A, Zucchi D, Silvagni E et al (2025) Systemic lupus erythematosus: one year in review 2025. Clin Exp Rheumatol 43:397\u2013406. https:\/\/doi.org\/10.55563\/clinexprheumatol\/m0pi1k","DOI":"10.55563\/clinexprheumatol\/m0pi1k"},{"key":"8455_CR3","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1002\/art.34672","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M, Purvey S, Fang H, Magder LS (2012) Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. Arthritis Rheum 64:4021\u20134028. https:\/\/doi.org\/10.1002\/art.34672","journal-title":"Arthritis Rheum"},{"key":"8455_CR4","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1136\/annrheumdis-2013-205171","volume":"74","author":"IN Bruce","year":"2015","unstructured":"Bruce IN, O\u2019Keeffe AG, Farewell V et al (2015) Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis 74:1706\u20131713. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205171","journal-title":"Ann Rheum Dis"},{"key":"8455_CR5","doi-asserted-by":"publisher","first-page":"e528","DOI":"10.1016\/S2665-9913(24)00121-8","volume":"6","author":"V Golder","year":"2024","unstructured":"Golder V, Kandane-Rathnayake R, Li N et al (2024) Association of sustained lupus low disease activity state with improved outcomes in systemic lupus erythematosus: a multinational prospective cohort study. Lancet Rheumatol 6:e528\u2013e536. https:\/\/doi.org\/10.1016\/S2665-9913(24)00121-8","journal-title":"Lancet Rheumatol"},{"key":"8455_CR6","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1136\/annrheumdis-2015-207726","volume":"75","author":"K Franklyn","year":"2016","unstructured":"Franklyn K, Lau CS, Navarra SV et al (2016) Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 75:1615\u20131621. https:\/\/doi.org\/10.1136\/annrheumdis-2015-207726","journal-title":"Ann Rheum Dis"},{"key":"8455_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/rheumatology\/kew377","volume":"56","author":"MWP Tsang-A-Sjoe","year":"2017","unstructured":"Tsang-A-Sjoe MWP, Bultink IEM, Heslinga M, Voskuyl AE (2017) Both prolonged remission and lupus low disease activity state are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology (Oxford) 56:121\u2013128. https:\/\/doi.org\/10.1093\/rheumatology\/kew377","journal-title":"Rheumatology (Oxford)"},{"key":"8455_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/annrheumdis-2017-211613","volume":"77","author":"M Zen","year":"2018","unstructured":"Zen M, Iaccarino L, Gatto M et al (2018) Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 77:104\u2013110. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211613","journal-title":"Ann Rheum Dis"},{"key":"8455_CR9","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1136\/annrheumdis-2013-205139","volume":"73","author":"RF van Vollenhoven","year":"2014","unstructured":"van Vollenhoven RF, Mosca M, Bertsias G et al (2014) Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis 73:958\u2013967. https:\/\/doi.org\/10.1136\/annrheumdis-2013-205139","journal-title":"Ann Rheum Dis"},{"key":"8455_CR10","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.rdc.2019.07.004","volume":"45","author":"M Aringer","year":"2019","unstructured":"Aringer M, Leuchten N, Schneider M (2019) Treat to target in systemic lupus erythematosus. Rheum Dis Clin North Am 45:537\u2013548. https:\/\/doi.org\/10.1016\/j.rdc.2019.07.004","journal-title":"Rheum Dis Clin North Am"},{"key":"8455_CR11","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1002\/acr.25690","volume":"78","author":"LR Sammaritano","year":"2026","unstructured":"Sammaritano LR, Askanase A, Bermas BL et al (2026) 2025 American College of Rheumatology (ACR) guideline for the treatment of systemic lupus erythematosus. Arthritis Care Res (Hoboken) 78:815\u2013839. https:\/\/doi.org\/10.1002\/acr.25690","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8455_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2024","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J et al (2024) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83:15\u201329. https:\/\/doi.org\/10.1136\/ard-2023-224762","journal-title":"Ann Rheum Dis"},{"key":"8455_CR13","doi-asserted-by":"publisher","first-page":"e208","DOI":"10.1016\/S2665-9913(19)30076-1","volume":"1","author":"RA Furie","year":"2019","unstructured":"Furie RA, Morand EF, Bruce IN et al (2019) Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial. Lancet Rheumatol 1:e208\u2013e219. https:\/\/doi.org\/10.1016\/S2665-9913(19)30076-1","journal-title":"Lancet Rheumatol"},{"key":"8455_CR14","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1912196","volume":"382","author":"EF Morand","year":"2020","unstructured":"Morand EF, Furie R, Tanaka Y et al (2020) Trial of anifrolumab in active systemic lupus erythematosus. N Engl J Med 382:211\u2013221. https:\/\/doi.org\/10.1056\/NEJMoa1912196","journal-title":"N Engl J Med"},{"key":"8455_CR15","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ard.2025.01.016","volume":"84","author":"EF Morand","year":"2025","unstructured":"Morand EF, van Vollenhoven R, Furie RA et al (2025) LLDAS and remission attainment with anifrolumab treatment in patients with systemic lupus erythematosus: results from the TULIP and long-term extension randomised controlled trials. Ann Rheum Dis 84:777\u2013788. https:\/\/doi.org\/10.1016\/j.ard.2025.01.016","journal-title":"Ann Rheum Dis"},{"key":"8455_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.55563\/clinexprheumatol\/728zl6","volume":"44","author":"P Classen","year":"2026","unstructured":"Classen P, Boedecker-Lips S, Tomalla V et al (2026) Anifrolumab in systemic lupus erythematosus: real-world experience from a single academic tertiary care centre. Clin Exp Rheumatol 44:93\u201399. https:\/\/doi.org\/10.55563\/clinexprheumatol\/728zl6","journal-title":"Clin Exp Rheumatol"},{"key":"8455_CR17","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3899\/jrheum.2024-0053","volume":"51","author":"C Tani","year":"2024","unstructured":"Tani C, Cardelli C, Zen M et al (2024) Anifrolumab in refractory systemic lupus erythematosus: a real-world, multicenter study. J Rheumatol 51:1096\u20131101. https:\/\/doi.org\/10.3899\/jrheum.2024-0053","journal-title":"J Rheumatol"},{"key":"8455_CR18","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1136\/ard-2022-222748","volume":"82","author":"EF Morand","year":"2023","unstructured":"Morand EF, Abreu G, Furie RA et al (2023) Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Ann Rheum Dis 82:639\u2013645. https:\/\/doi.org\/10.1136\/ard-2022-222748","journal-title":"Ann Rheum Dis"},{"key":"8455_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2021-000538","volume":"8","author":"RF van Vollenhoven","year":"2021","unstructured":"van Vollenhoven RF, Bertsias G, Doria A et al (2021) 2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 8:e000538. https:\/\/doi.org\/10.1136\/lupus-2021-000538","journal-title":"Lupus Sci Med"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08455-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08455-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08455-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T23:07:35Z","timestamp":1791241655000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08455-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,5]]},"references-count":19,"alternative-id":["8455"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08455-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,5]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice principles. Approval was obtained from the Clinical Research Ethics Committee of Hospital Universitario Cl\u00ednico San Carlos, Madrid, Spain, on 21 March 2024 (protocol number: CEIm 24\/215-E).","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was not required according to national legislation governing observational studies (Real Decreto 957\/2020).","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"DFN has received fees from AstraZeneca for advisory\/consultancy activities unrelated to the present study. AstraZeneca had no role in the design, conduct, analysis, interpretation, or reporting of this study, and no funding from AstraZeneca was received for this work. The remaining authors declare no competing interests relevant to this study.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"OpenAI ChatGPT was used during manuscript preparation and revision from approximately April to September 2026, solely for language editing, wording, and manuscript organisation. GPT-5.6 Sol was used during the final revision in September 2026. No scientific content, data, statistical analyses, results, or conclusions were generated by AI. All AI-assisted text was critically reviewed and verified by the authors. This manuscript is original and has not been copied, posted online, or published elsewhere.","order":4,"name":"Ethics","label":"Use of artificial intelligence","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Preliminary results from this study were presented at the 52nd National Congress of the Spanish Society of Rheumatology (SER), Bilbao, Spain, 5\u20138 May 2026, and published as congress abstract P142, \u201cResultados en vida real con anifrolumab en lupus eritematoso sist\u00e9mico seg\u00fan objetivos treat-to-target (ACR 2025),\u201d in Reumatolog\u00eda Cl\u00ednica. 2026;22(Suppl 2):S274.","order":5,"name":"Ethics","label":"Previous presentation","group":{"name":"EthicsHeading","label":"Declarations"}}]}}